Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Polar Capital Holdings Plc

Polar Capital Holdings Plc reduced its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 50.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 176,520 shares of the biotechnology company's stock after selling 176,508 shares during the period. Polar Capital Holdings Plc owned 0.23% of Axon Enterprise worth $104,909,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in AXON. New Wave Wealth Advisors LLC acquired a new position in Axon Enterprise in the fourth quarter valued at approximately $40,000. Y.D. More Investments Ltd acquired a new position in Axon Enterprise in the fourth quarter valued at approximately $45,000. Stonebridge Financial Group LLC acquired a new position in Axon Enterprise in the fourth quarter valued at approximately $53,000. GPS Wealth Strategies Group LLC lifted its holdings in Axon Enterprise by 74.1% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 40 shares during the last quarter. Finally, Berbice Capital Management LLC acquired a new position in Axon Enterprise in the fourth quarter valued at approximately $59,000. Hedge funds and other institutional investors own 79.08% of the company's stock.

Axon Enterprise Stock Up 0.7%

Shares of Axon Enterprise stock traded up $4.79 during trading hours on Friday, reaching $733.18. 419,101 shares of the company were exchanged, compared to its average volume of 759,084. Axon Enterprise, Inc. has a 1 year low of $273.52 and a 1 year high of $735.68. The stock's fifty day moving average is $584.61 and its 200 day moving average is $594.51. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The firm has a market cap of $57.08 billion, a PE ratio of 189.45, a PEG ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.34 by $0.07. The firm had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. Axon Enterprise's revenue for the quarter was up 31.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.15 earnings per share. As a group, equities research analysts forecast that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $540.99, for a total value of $5,409,900.00. Following the completion of the transaction, the chief executive officer now owns 3,063,982 shares in the company, valued at $1,657,583,622.18. This represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Matthew R. Mcbrady sold 400 shares of the company's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $718.40, for a total transaction of $287,360.00. Following the completion of the transaction, the director now owns 3,492 shares of the company's stock, valued at $2,508,652.80. This represents a 10.28% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,764 shares of company stock valued at $14,856,635 over the last quarter. 4.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

AXON has been the topic of a number of research analyst reports. JMP Securities reissued an "outperform" rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Craig Hallum lowered Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. Barclays boosted their target price on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Needham & Company LLC boosted their target price on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, Northcoast Research lowered Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $652.73.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.